Sunshine Biopharma, Inc. (SBFM )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol SBFM
- Company Sunshine Biopharma, Inc.
- Price $0.84
- Changes Percentage -18.34
- Change -0.1889
- Day Low $0.84
- Day High $1.01
- Year High $24.3
- Year Low $1.03
- Market Cap $2,758,847
- Price Avg 50 EMA (D) $1.71
- Price Avg 200 EMA (D) $8.8
- Exchange NASDAQ
- Volume 96,615
- Average Volume 642,804
- Open $0.91
- Previous Close $1.03
- EPS -6.08
- PE -0.19
- Earnings Announcement 2026-11-12 05:00:00
- Shares Outstanding $2,378,316
Company brief: SUNSHINE BIOPHARMA, INC. (SBFM )
- Healthcare
- Drug Manufacturers - Specialty & Generic
- Dr. Steve N. Slilaty Ph.D.
- https://www.sunshinebiopharma.com
- CA
- N/A
- 02-15-2022
- US8677814035
Sunshine Biopharma, Inc., a pharmaceutical and nutritional supplement company, focuses on the research and development of anticancer drugs. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; and SBFM-PL4, an anti-coronavirus treatment compound. It also offers Essential 9, a nutritional supplement tablet; and Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name, as well as develops and markets other science-based nutritional supplements. The company has a license agreement with the University of Georgia to advance the development of its anti-coronavirus lead compound, SBFM-PL4. Sunshine Biopharma, Inc. is headquartered in Pointe-Claire, Canada.